Source: International Congress 2018 – Clinical trials in COPD: new results
Disease area: Airway diseases



Rating:

Share or cite this content

Citations should be made in the following way:
M. Tabberer (Middlesex, United Kingdom), C. Jones (Research Triangle Park, United States of America), S. Kilbride (Middlesex, United Kingdom), G. Criner (Philadelphia, United States of America), P. Lange (Copenhagen, Denmark), M. Han (Ann Arbor, United States of America), F. Martinez (New York, United States of America), D. Lipson (King of Prussia, United States of America). Single inhaler triple therapy in patients with COPD: response rates in health-related quality of life in the IMPACT Trial. 1658

Member's Comments

No comment yet.

Related content which might interest you: Single inhaler triple therapy in patients with COPD: patient-reported dyspnoea and health status from the IMPACT Trial Source: International Congress 2018 – Integrating pharmacological and non-pharmacological management in COPD: are we there yet? Year: 2018 TriOptimize VII: Improvement of health-related quality of life after 3 months treatmentwith extrafine single inhaler triple therapy in COPD patients in a real-world setting. Source: Virtual Congress 2020 – Clinical studies of COPD: combination inhalers and much more Year: 2020 Indacaterol once-daily improves health-related quality of life (HRQOL) in COPD patients: a 52-week study Source: Annual Congress 2009 - New bronchodilators Year: 2009 Late Breaking Abstract - Extrafine single inhaler triple therapy improves quality of life in COPD. Analysis of SGRQ subdomains of the TRIBUTE Study Source: International Congress 2018 – COPD: from LABA/ICS to LABA/LAMA/ICS Year: 2018 NVA237 once daily improves dyspnea and health-related quality of life (HRQoL) in patients with COPD: The GLOW1 trial Source: Annual Congress 2011 - Bronchodilators in asthma and COPD Year: 2011 Examination of variations in responder rates in COPD clinical trial outcomes Source: Annual Congress 2013 –COPD drugs: new findings Year: 2013 Effect of a self-management programme on health-related quality of life in COPD patients: a randomised controlled trial Source: Eur Respir J 2002; 20: Suppl. 38, 377s Year: 2002 Dual bronchodilation with once-daily QVA149 improves dyspnea and health status and reduces symptoms and rescue medication use in patients with COPD: The IGNITE trials Source: Annual Congress 2013 –New clinical trials of asthma and COPD drugs Year: 2013 A prospective observational study of the impact of COPD on daily life following the initiation of indacaterol Source: International Congress 2014 – Clinical assessment of airway diseases Year: 2014 Tiotropium + olodaterol fixed-dose combination shows clinically meaningful improvements in quality of life versus placebo Source: International Congress 2015 – New data on established treatments for asthma, COPD and bronchiectasis Year: 2015 A placebo controlled trial with inhaled mannitol improves health related quality of life in patients with bronchiectasis Source: Annual Congress 2004 - Bronchiectasis Year: 2004 LATE-BREAKING ABSTRACT: Cost-effectiveness of the LABA/LAMA dual bronchodilator QVA149 in a Swedish setting Source: Annual Congress 2013 –Health economics of airway diseases Year: 2013 Impact of asthmatic patient satisfaction with the inhaler upon adherence, disease control and quality of life. Results of the ASCONA study Source: International Congress 2017 – Pulmonary drug and devices delivery Year: 2017 Indacaterol once-daily improves health-related quality of life in COPD patients: a 26-week comparison with placebo and tiotropium Source: Annual Congress 2009 - New bronchodilators Year: 2009 Single inhaler triple therapy in patients with advanced COPD (FULFIL): exacerbation/pneumonia composite outcomes Source: International Congress 2017 – COPD management Year: 2017 Economic evaluation of the impact of exacerbation frequency in COPD patients treated with single-inhaler triple therapy in Spain: The IMPACT trial Source: Virtual Congress 2020 – Pharmacological management of COPD Year: 2020 Late Breaking Abstract - IMPACT study — single inhaler triple therapy (FF/UMEC/VI) versus FF/VI and UMEC/VI in patients with COPD: healthcare resource utilization and costs — UK Source: International Congress 2018 – COPD: from LABA/ICS to LABA/LAMA/ICS Year: 2018 Evaluation of quality of life (QOL) in asthma patients during 6 months formoterol therapy Source: Eur Respir J 2001; 18: Suppl. 33, 44s Year: 2001 Health-related quality of life (HRQL) and use of formoterol in patients with COPD Source: Eur Respir J 2001; 18: Suppl. 33, 55s Year: 2001 Effect of tele healthcare on quality of life in patients with severe COPD: a randomized clinical trial Source: International Congress 2017 – Best abstracts in physical activity and management of COPD Year: 2017